Expansion of our technologies to assess groups of acrylamide-based inhibitors with varying linkers and scaffolds and comparisons with known potency of such inhibitors with KRAS-driven cancer cells in culture or during patient treatments is likely to provide much-needed insight into mechanistic reasons for variations in potency. Here, KRAS is linked to cancer.